Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal vaccine conjugate 13-valent - Pfizer

Next Previous
Drug Profile

Pneumococcal vaccine conjugate 13-valent - Pfizer

Alternative Names: 13-Valent pneumococcal conjugate vaccine - Pfizer; 13vPnC; PCV 13; PNCRM13; Pneumococcal 13-valent conjugate vaccine - Pfizer; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Pfizer; Prevenar 13; Prevnar 13

Latest Information Update: 27 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Cochin Hospital; Pfizer; University Hospital of Montpellier; Wyeth
  • Class Conjugate vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pneumococcal infections

Most Recent Events

  • 31 Dec 2022 The European Patent Office revokes European patent related to 13-valent pneumococcal conjugate vaccine , prior to December 2022
  • 04 Nov 2022 Pfizer initiates enrolment in a phase III trial for Pneumococcal infections (In infants, Prevention) in China(IM) (NCT05759520)
  • 02 Nov 2022 Wuhan BravoVax plans a phase I trial for Pneumococcal infections (Prevention, In infants, In children, In adolescents, In adults and In the elderly) (IM) in November 2022 (NCT05602480)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top